Syndax Pharmaceuticals Inc — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Syndax announced on November 2, 2026 that Chief Financial Officer Keith Goldan is retiring and will be succeeded by Aaron A. Ondrey, effective November 9, 2026. Ondrey brings over 25 years of biotech finance and operational leadership experience, with expertise in financial management, corporate strategy, commercialization, and M&A. The appointment was made concurrent with strong 3Q26 results: $83.3M total revenue ($60.7M Revuforj, $22.6M Niktimvo collaboration revenue), 90% YoY growth in Revuforj net revenue, and $551.1M cash position.
Why this rating
Routine executive succession at company scale; no financial impact disclosed, normal personnel change; operational continuity maintained with incoming CFO's deep sector experience
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.